iconstar paper   HIV Articles  
Back grey arrow rt.gif
 
 
LA Cabotegavir & Rilpivirine During Pregnancy
 
 
  Rilpivirine PK in HIV+ pregnant women
 
FIGURE 1. Rilpivirine median plasma concentrations over time. Nonpregnant reference exposure was determined from package insert.12 Error bars are standard error of the median.
 
Pdf attached

0425231

Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living With HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials - ID Week 2021 Patel. (09/30/21)
 
Rilpivirine
MATERNAL DOLUTEGRAVIR (DTG) USE, AND PREGNANCY AND BIRTH OUTCOMES: THE ANTIRETROVIRAL PREGNANCY REGISTRY (APR) - (09/29/21)
 
Long acting injectable cabotegravir: updated efficacy and safety results from HPTN 084
 
AIDS 2022
 
S Delany-Moretlwe et al.
on behalf of the HPTN 084 study team

0425232

0425233

0425234

0425235

0425236

0425237

0425238

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org